Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 1c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $163 thousand versus the consensus estimate of $58.75 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• TD Cowen Resumes Keyera Corp. (KEY:CN) (KEYUF) at Buy
• Sandisk (SNDK) call put ratio 1 call to 1.2 puts a focus on June 26 weekly 1290 puts into Korean market weakness and Micron (MU) quarter results